Pfizer’s Comirnaty mRNA COVID Vaccine Manufacturing Has Dropped by 89% Due to Decrease in Demand

The Follow the Money Team’s new report on Pfizer’s financials, based on Pfizer’s Q1 2023 reporting, offers many important insights:

Pfizer reports that its mRNA COVID vaccine, Comirnaty^®, manufacturing activities, performed on behalf of BioNTech, dropped 89% to only $5 million quarter-over-quarter.
In its Q1 2023 report, Pfizer assumes no growth in market share for COVID-19 vaccinations.
Pfizer notes the Comirnaty’s decrease in uptake is due to “fewer primary vaccinations and non-compliance.”
Pfizer’s Q1 2023 revenue was down 28.7%, and Earnings Per Share dropped 29% from Q1 2022.
Pfizer’s 2023 revenue guidance is about $30 billion lower than 2022.
The company’s stock price has dropped from a high of $59.48 on December 17, 2021, to a 52-week low of $36.51 on May 17, 2023, a 37% fall in just over 12 months.

By David Shaw

Follow The Money (FTM) Pfizer Financial Performance Micro Report PDF

Pfizer Documents Analysis Reports